GU Cancers 2019 | 177Lu-PSMA-617 radionuclide therapy in mCRPC

Scott Tagawa, MD, MS, of the Weill Cornell Medicine, New York City, NY, talks about the use of lutetium-177 [177Lu]-prostate-specific membrane antigen (PSMA)-617 (177Lu-PSMA-617) in patients with metastatic castration-resistant prostate cancer (mCRPC). Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Prof. Tagawa highlights the need to optimize the delivery mode of the radionuclide therapy in order to minimize off-target effects while maximizing tumor-targeted effects.